UKIPO report of IP trends for UK Higher Education Institutions highlights life sciences innovation

No items found.
​
April 30, 2020
#
Life
Table of contents
  • Toc Heading
  • Toc Heading

On 29 April 2020, the UKIPO published an overview report of IP trends for UK Higher Education Institutions (HEIs) and their spin-out businesses, between 1999 and 2018. We focus on some of the main takeaways and trends from this overview for the life sciences sector below.

The report highlights the value that UK universities place on life sciences innovation, as reflected by the impressive percentage of patent publications in the fields of Biotechnology and Pharmaceuticals. Indeed, 47 % of UK HEI patent publications are in the Chemistry sector (over 50% of which used pharmaceuticals and biotechnology IPC technology fields), compared to 21% of all patent publications globally.

Notably, there was a rise in the level of international collaboration between UK HEIs and entities abroad, particularly in the US. This trend demonstrates both the aim of universities to more effectively exploit their IP commercially and the importance of collaboration for the transfer of technology.

Life sciences powerhouses Imperial College London, UCL and Oxford University were among those institutions showing not only the largest output of published applications, but also the greatest proportional increase in activity. Furthermore, of the top 10 spin-out businesses, according to the number of applications, six of these have a biotechnological focus, including DNA sequencing products, biotherapeutics and drug discovery.

The importance of innovation within the life sciences sector to UK universities, and the UK as a whole, is clear from this report. As we move into the era of personalised medicine and with Artificial Intelligence and machine learning becoming increasingly significant in healthcare innovation, it will be interesting to see whether UK HEIs continue to lead in this new era and whether more and more computer technology related patent filings over the next 20 years will be important to the healthcare sector.

Recent Case Reports

See all Case Reports

UPC Court of appeal issues final decision, despite no finding on infringement at first instance
30 March 2026
In Rematec v Europe Forestry, the UPC Court of Appeal overturned the Mannheim Local Division’s revocation of the patent and, applying Article 75(1) UPCA, issued a final decision on both validity and infringement despite no infringement finding at first instance. The Court adopted a narrower, description‑led approach to claim interpretation, confirmed the patent’s validity, found infringement, and granted final remedies without referring the case back to the Court of First Instance.
​
Litigation insurance as security for costs
30 March 2026
In Syntorr v Arthrex, the UPC Court of Appeal clarified that while litigation insurance is not itself a form of security under Rule 158 RoP, it is a relevant factor when deciding whether security for costs should be ordered at all. By failing to consider the claimant’s insurance policy, the Munich Local Division wrongly exercised its discretion. The Court set aside the €2 million security order and confirmed that insurance can mitigate concerns about cost recoverability.
​
National law applies to claims for loss of profit if the events occurred before the UPC came into force
30 March 2026
In Fives v REEL, the Hamburg Local Division of the UPC dismissed a standalone damages action despite prior findings of infringement. Although the UPC was competent to assess damages, the court held that national law applied because the relevant events pre‑dated the UPC’s entry into force. Applying German law, the court found that the claimant had not proven causation or lost profit, highlighting the demanding evidentiary burden for price‑reduction damages claims and the importance of substantiating counterfactual tender outcomes.
​